Cerebrospinal Fluid Biomarkers for Differentiation of Frontotemporal Lobar Degeneration from Alzheimer’s Disease

Frontiers in Aging Neuroscience

John Q Trojanowski¹  Murray eGrossman¹  David J Irwin¹ 

[1] University of Pennsylvania;

关键词: Cerebrospinal Fluid;    Frontotemporal Dementia;    biomarker;    Alzheimer’s disease;    tau;    primary progressive aphasia;   

DOI  :  10.3389/fnagi.2013.00006

来源: DOAJ

【 摘 要 】

Accurate ante mortem diagnosis in frontotemporal lobar degeneration (FTLD) is crucial to the development and implementation of etiology-based therapies. Several neurodegenerative disease-associated proteins, including the major protein constituents of inclusions in Alzheimer’s disease (AD) associated with amyloid-beta (Aβ1-42) plaque and tau neurofibrillary tangle pathology, can be measured in cerebrospinal fluid (CSF) for diagnostic applications. Comparative studies using autopsy-confirmed samples suggest that CSF total-tau (t-tau) and Aβ1-42 levels can accurately distinguish FTLD from AD, with a high t-tau to Aβ1-42 ratio diagnostic of AD; however, there is also an urgent need for FTLD-specific biomarkers. These analytes will require validation in large autopsy-confirmed cohorts and face challenges of standardization of within- and between-laboratory sources of error. In addition, CSF biomarkers with prognostic utility and longitudinal study of CSF biomarker levels over the course of disease are also needed. Current goals in the field include identification of analytes that are easily and reliably measured and can be used alone or in a multi-modal approach to provide an accurate prediction of underlying neuropathology for use in clinical trials of disease modifying treatments in FTLD.To achieve these goals it will be of the utmost importance to view neurodegenerative disease, including FTLD, as a clinicopathological entity, rather than exclusively a clinical syndrome.

【 授权许可】

Unknown